News

Apply Now: 📣 BLUE KNIGHT ™️ Resident QuickFire Challenge: Accelerating Project NextGen

Johnson & Johnson Innovation, together with the Biomedical Advanced Research and Development Authority (BARDA), is proud to launch the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen.

Current and alumni Blue Knight residents and their collaborators are invited to submit promising potential pre-clinical or clinical solutions for the opportunity to receive award funding from a total pool of $10M to help them accelerate their potential vaccines, therapeutics, and enabling technologies.

Applicants can apply to one or both application tracks:

  • Partner: Forging collaborations can accelerate evidence generation to get to key inflection points, allowing for more rapidly deployable potential solutions that provide mutual value. For the ‘Partner’ track of this challenge, Blue Knight residents who choose to collaborate with another Blue Knight or early-stage company in their submission may apply through a joint application submission.*
  • Sole Contributor: Blue Knight residents are invited to apply to accelerate their potential solution.**

All awards are subject to the execution of the necessary (award) agreements.

*Applicants must have at least one Blue Knight resident, current or alumni, as a collaborator
**Applicants must be current or alumni Blue Knight residents

 

Learn more here.

Recent News

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital

06/25/2025

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S.

06/24/2025

AgroSpheres and Wilbur-Ellis Launch FUN-THYME™, a Powerful Broad-Spectrum Biofungicide Built on Novel AgriCell® Technology

AgroSpheres, a biotechnology company transforming crop protection with biobased innovations, today announced the commercial launch of FUN-THYME™, a groundbreaking, broad-spectrum biofungicide derived from thyme oil and delivered through the company’s proprietary AgriCell encapsulation platform. Through an exclusive distribution agreement, Wilbur-Ellis will introduce FUN-THYME™ to growers across the United States, helping them protect high-value crops including